相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Non-Small Cell Lung Cancer, Version 2.2021 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Non-small-cell lung cancer with ERBB2 mutation in non-tyrosine kinase domain benefits from pyrotinib: A case report
Jun Ni et al.
THORACIC CANCER (2021)
Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer
Chia-Chi Hsu et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
The World Cancer Research Fund/American Institute for Cancer Research Third Expert Report on Diet, Nutrition, Physical Activity, and Cancer: Impact and Future Directions
Steven K. Clinton et al.
JOURNAL OF NUTRITION (2020)
Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma
Wenfeng Fang et al.
ONCOLOGIST (2020)
Pilot evaluation of a HER2 testing in non-small-cell lung cancer
Katsuyuki Hotta et al.
JOURNAL OF CLINICAL PATHOLOGY (2020)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
R. K. Murthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
T. Mok et al.
ANNALS OF ONCOLOGY (2020)
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.
Egbert F. Smit et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
Junji Tsurutani et al.
Cancer Discovery (2020)
Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer
Xue-Wu Wei et al.
THORACIC CANCER (2020)
Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib
Bo Yuan et al.
FRONTIERS IN ONCOLOGY (2020)
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paul K. Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study
Caicun Zhou et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer
Juergen Wolf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study
W. Victoria Lai et al.
EUROPEAN JOURNAL OF CANCER (2019)
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)
Rafal Dziadziuszko et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
114OPotential resistance mechanisms using next generation sequencing from Chinese EGFR T790M+ non-small cell lung cancer patients with primary resistance to osimertinib: A multicenter study
C Xu et al.
ANNALS OF ONCOLOGY (2019)
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres et al.
ANNALS OF ONCOLOGY (2019)
A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY)
Kiichiro Ninomiya et al.
CHEST (2019)
Time to tackle the blood-brain barrier in HER2-mutant lung cancer
Jessica J. Lin et al.
CANCER (2019)
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
Y. Wang et al.
ANNALS OF ONCOLOGY (2019)
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers
Solange Peters et al.
CLINICAL CANCER RESEARCH (2019)
Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib
Shengwu Liu et al.
CLINICAL CANCER RESEARCH (2018)
High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2
Masaaki Nagano et al.
CLINICAL CANCER RESEARCH (2018)
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial
Yeon Hee Park et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
Bob T. Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
John D. Hainsworth et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer
Katsuyuki Hotta et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer
Jacqulyne P. Robichaux et al.
NATURE MEDICINE (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment
Adrianus J. de Langen et al.
BRITISH JOURNAL OF CANCER (2018)
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program
Solange Peters et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
David M. Hyman et al.
NATURE (2018)
LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
S S Ramalingam et al.
ANNALS OF ONCOLOGY (2018)
Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients
Zhefeng Liu et al.
ONCOTARGETS AND THERAPY (2018)
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Silvia La Monica et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
NGS Sequencing Based Liquid / Tissue Biopsy Identified Coexistence of HER2 Amplification and Mutation in Advanced NSCLC Patients
R. Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Short-Term Culture of Patient Derived Tumor Organoids Identify Neratinib/Trastuzumab as an Effective Combination in HER2 Mutant Lung Cancer
E. Ivanova et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
HER2 Transmembrane Domain Mutations: Rare New Target for Non-Small Cell Lung Cancer Therapy
Hirotsugu Notsuda et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodirnerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib
Sai-Hong Ignatius Ou et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
Toshihiko Doi et al.
LANCET ONCOLOGY (2017)
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
J. Mazieres et al.
ANNALS OF ONCOLOGY (2016)
Cancer Statistics in China, 2015
Wanqing Chen et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers
Bob T. Li et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2 - mutant or amplified tumors
M. G. Kris et al.
ANNALS OF ONCOLOGY (2015)
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
D. Planchard et al.
ANNALS OF ONCOLOGY (2015)
Targeting HER2 for the Treatment of Breast Cancer
Mothaffar F. Rimawi et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma
Jacques De Greve et al.
LUNG CANCER (2015)
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
Daniele Cretella et al.
MOLECULAR CANCER (2014)
HER2 status in lung adenocarcinoma: A comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations
Akihiko Yoshizawa et al.
LUNG CANCER (2014)
Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study
Mariam Jamal-Hanjani et al.
PLOS BIOLOGY (2014)
HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients
V. Martin et al.
BRITISH JOURNAL OF CANCER (2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
Julien Mazieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The quest to overcome resistance to EGFR-targeted therapies in cancer
Curtis R. Chong et al.
NATURE MEDICINE (2013)
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S. Peters et al.
ANNALS OF ONCOLOGY (2012)
Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas
Maria E. Arcila et al.
CLINICAL CANCER RESEARCH (2012)
Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains
Chenguang Li et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu
J. De Greve et al.
LUNG CANCER (2012)
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2
Heidi Greulich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation
Ken Takezawa et al.
CANCER DISCOVERY (2012)
Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers
Kenji Tomizawa et al.
LUNG CANCER (2011)
Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers
Chenguang Li et al.
PLOS ONE (2011)
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
Kimio Yonesaka et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program
Karynsa Cetin et al.
Clinical Epidemiology (2011)
Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer
Helen J. Ross et al.
CLINICAL CANCER RESEARCH (2010)
Clinical Significance of Epidermal Growth Factor Receptors in Non-small Cell Lung Cancer and a Prognostic Role for HER2 Gene Copy Number in Female Patients
Samer Al-Saad et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
The Role of Human Epidermal Growth Factor Receptor 2 as a Prognostic Factor in Lung Cancer A Meta-Analysis of Published Data
Lingxiang Liu et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients
F. Cappuzzo et al.
ANNALS OF ONCOLOGY (2009)
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Jose Baselga et al.
NATURE REVIEWS CANCER (2009)
Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer
Shoichi Kuyama et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non-small cell lung cancer
Roy S. Herbst et al.
CLINICAL CANCER RESEARCH (2007)
Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer
Bruce E. Johnson et al.
CLINICAL CANCER RESEARCH (2006)
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors
Shizhen Emily Wang et al.
CANCER CELL (2006)
Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma
LM Krug et al.
CANCER (2005)
Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2 -: 39810:: A Phase II trial of cancer and leukemia group B
G Clamon et al.
CANCER (2005)
Trastuzumab in the treatment of advanced non-small-cell lung cancer: Is there a role? Focus on eastern cooperative oncology group study 2598
CJ Langer et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Intragenic ERBB2 kinase mutations in tumours
P Stephens et al.
NATURE (2004)
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer
U Gatzemeier et al.
ANNALS OF ONCOLOGY (2004)
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
HS Cho et al.
NATURE (2003)
分享论文
